financetom
Business
financetom
/
Business
/
Kohl's Lowers Full-Year Outlook as Third-Quarter Sales Fall More Than Projected
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kohl's Lowers Full-Year Outlook as Third-Quarter Sales Fall More Than Projected
Nov 26, 2024 9:00 AM

11:37 AM EST, 11/26/2024 (MT Newswires) -- Shares of Kohl's (KSS) plunged intraday Tuesday after the retailer reported a bigger-than-expected decline in fiscal third-quarter revenue and lowered its full-year financial outlook, a day after the department store chain announced a chief executive transition plan.

Sales dropped to $3.51 billion for the three-month period ended Nov. 2 from $3.84 billion a year ago and missed the $3.64 billion average analyst estimate on FactSet. Earnings per share more-than-halved to $0.20 from $0.53.

"Our third quarter results did not meet our expectations as sales remained soft in our apparel and footwear businesses," CEO Tom Kingsbury, who will step down on Jan. 15, said in a statement.

Shares of Kohl's tumbled 20% in Tuesday trade.

Strong performance across key growth areas, including makeup shop Sephora and home decor, as well as the opening of Babies "R" Us shops in 200 stores, was offset by declines in the core business, according to Kingsbury. "We are not satisfied with our performance in 2024 and are taking aggressive action to reverse the sales declines," he said.

Kohl's announced late Monday that retail veteran Ashley Buchanan, who has been CEO of arts-and-crafts retailer Michaels since 2020, will become the company's next CEO. Kingsbury will serve in an advisory role and retain his position on the Kohl's board until May when he retires.

Management now expects full-year sales to decline 7% to 8% from fiscal 2023's sales of $16.59 billion. That's down from the 4% to 6% decrease it guided for in August. The market view on FactSet is for sales of $15.66 billion in the ongoing year. The new outlook projects a 6% to 7% decrease in comparable sales, worse than the previous expectation of a 3% to 5% decline.

The company sees full-year EPS in the $1.20 to $1.50 range, below its August guidance of between $1.75 and $2.25. Kohl's dampened operating margin expectations to between 3% and 3.2% from 3.4% to 3.8% previously.

"We are approaching our financial outlook for the year more conservatively given the third quarter underperformance and our expectation for a highly competitive holiday season," Kingsbury said.

Price: 14.69, Change: -3.65, Percent Change: -19.90

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Netflix, Warner Music Group Partner to Develop Artist Documentary Projects
Netflix, Warner Music Group Partner to Develop Artist Documentary Projects
Mar 20, 2026
01:32 PM EDT, 03/20/2026 (MT Newswires) -- Netflix ( NFLX ) and Warner Music Group ( WMG ) have signed an exclusive multi-year first-look agreement for documentary series and films exploring the lives and legacies of the label's artists and songwriters, Warner Music Group ( WMG ) said Friday. The financial terms of the partnership were not disclosed. Under the...
Netflix, Warner Music strike multi-year deal for artist documentaries
Netflix, Warner Music strike multi-year deal for artist documentaries
Mar 20, 2026
March 20 (Reuters) - Netflix ( NFLX ) and Warner Music Group ( WMG ) have signed an exclusive multi-year deal to produce documentary series and films exploring the lives, music and legacies of the label's storied artist roster. The partnership, announced on Friday, hands Netflix ( NFLX ) access to one of the most formidable vaults in music history....
ImmunityBio Wins Macau Approval for Anktiva in Bladder Cancer
ImmunityBio Wins Macau Approval for Anktiva in Bladder Cancer
Mar 20, 2026
01:33 PM EDT, 03/20/2026 (MT Newswires) -- ImmunityBio ( IBRX ) said Friday that the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China, approved Anktiva, or nogapendekin alfa inbakicept-pmln, marking the drug's first authorization in Asia. The drug is approved for use in combination with Bacillus Calmette-Guerin to treat adults with BCG-unresponsive non-muscle invasive bladder cancer, including carcinoma...
Super Micro Shares Under Pressure As Company Responds To Indictment
Super Micro Shares Under Pressure As Company Responds To Indictment
Mar 20, 2026
Super Micro Computer Inc ( SMCI ) shares hit a fresh 52-week low Friday afternoon as selling pressure intensified following a Justice Department case tied to individuals connected to the company. Here’s what investors need to know. Super Micro Computer ( SMCI ) stock is at significant support. What’s pressuring SMCI? SMCI Stock Falls After DOJ Export Charges Friday’s drop...
Copyright 2023-2026 - www.financetom.com All Rights Reserved